These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 9392488)

  • 1. Assessment of hepatic sensitivity to glucagon in NIDDM: use as a tool to estimate the contribution of the indirect pathway to nocturnal glycogen synthesis.
    Nielsen MF; Wise S; Dinneen SF; Schwenk WF; Basu A; Rizza RA
    Diabetes; 1997 Dec; 46(12):2007-16. PubMed ID: 9392488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hepatic glycogen content on hepatic insulin action in humans: alteration in the relative contributions of glycogenolysis and gluconeogenesis to endogenous glucose production.
    Wise S; Nielsen M; Rizza R
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1828-33. PubMed ID: 9177391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol.
    Basu A; Caumo A; Bettini F; Gelisio A; Alzaid A; Cobelli C; Rizza RA
    Diabetes; 1997 Mar; 46(3):421-32. PubMed ID: 9032098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
    Shah P; Vella A; Basu A; Basu R; Schwenk WF; Rizza RA
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4053-9. PubMed ID: 11095432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
    Basu R; Basu A; Nielsen M; Shah P; Rizza RA
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2314-9. PubMed ID: 10404795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake.
    Nielsen MF; Basu R; Wise S; Caumo A; Cobelli C; Rizza RA
    Diabetes; 1998 Nov; 47(11):1735-47. PubMed ID: 9792543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
    Orskov L; Alberti KG; Mengel A; Møller N; Pedersen O; Rasmussen O; Seefeldt T; Schmitz O
    Diabetologia; 1991 Jul; 34(7):521-6. PubMed ID: 1916058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast.
    Clore JN; Post EP; Bailey DJ; Nestler JE; Blackard WG
    J Clin Endocrinol Metab; 1992 Mar; 74(3):660-6. PubMed ID: 1740502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.
    Basu A; Basu R; Shah P; Vella A; Johnson CM; Nair KS; Jensen MD; Schwenk WF; Rizza RA
    Diabetes; 2000 Feb; 49(2):272-83. PubMed ID: 10868944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.
    Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk FW; Holst JJ; Rizza RA
    Diabetes; 2001 Mar; 50(3):565-72. PubMed ID: 11246876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration.
    Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk WF; Rizza RA
    Diabetologia; 2001 Jun; 44(6):729-37. PubMed ID: 11440366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
    Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
    Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.
    Matsuda M; Defronzo RA; Glass L; Consoli A; Giordano M; Bressler P; Delprato S
    Metabolism; 2002 Sep; 51(9):1111-9. PubMed ID: 12200754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of gluconeogenesis after a 3-day fast does not deplete liver glycogen in patients with NIDDM.
    Clore JN; Blackard WG
    Diabetes; 1994 Feb; 43(2):256-62. PubMed ID: 8288050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
    Meyer C; Stumvoll M; Nadkarni V; Dostou J; Mitrakou A; Gerich J
    J Clin Invest; 1998 Aug; 102(3):619-24. PubMed ID: 9691098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration.
    Katz H; Homan M; Jensen M; Caumo A; Cobelli C; Rizza R
    Diabetes; 1994 Feb; 43(2):289-96. PubMed ID: 8288053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamine and alanine metabolism in NIDDM.
    Stumvoll M; Perriello G; Nurjhan N; Bucci A; Welle S; Jansson PA; Dailey G; Bier D; Jenssen T; Gerich J
    Diabetes; 1996 Jul; 45(7):863-8. PubMed ID: 8666134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes.
    Lewis GF; Carpentier A; Vranic M; Giacca A
    Diabetes; 1999 Mar; 48(3):570-6. PubMed ID: 10078558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of lack of suppression of glucagon on glucose tolerance in humans.
    Shah P; Basu A; Basu R; Rizza R
    Am J Physiol; 1999 Aug; 277(2):E283-90. PubMed ID: 10444424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.